Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ucb S.A.
(OP:
UCBJF
)
165.75
UNCHANGED
Streaming Delayed Price
Updated: 2:15 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
165.75
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
165.75
Today's Range
165.75 - 165.75
52wk Range
69.70 - 171.30
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
January 02, 2024
Tuesday, Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of...
Via
Benzinga
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
September 28, 2023
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.
Via
Benzinga
Performance
YTD
+65.75%
+65.75%
1 Month
+10.61%
+10.61%
3 Month
+10.61%
+10.61%
6 Month
+50.20%
+50.20%
1 Year
+92.08%
+92.08%
More News
Read More
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
August 31, 2023
Via
Benzinga
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
June 27, 2023
Via
Benzinga
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
February 14, 2023
Via
Benzinga
UCB's Rare Childhood Epilepsy Drug Scores FDA Approval
March 28, 2022
Via
Benzinga
Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane
February 08, 2022
Via
Benzinga
UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study
January 21, 2022
Via
Benzinga
UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights
January 19, 2022
Via
Benzinga
UCB Gets EU Approval For Bimekizumab In Psoriasis
August 25, 2021
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.